NEJM· @NEJM · X·· 25 天前精选AI 评分67
AI 导读
NEJM披露的III期随机试验I CAN中期分析显示,终末补体抑制剂ravulizumab在成人IgA肾病患者中降低蛋白尿的幅度显著大于安慰剂。该结果在#KidneyWk上公布,完整结果见nej.md/4iwTFdS。
推荐理由
III期I CAN试验的中期分析显示,ravulizumab在IgA肾病患者中降低蛋白尿的幅度显著优于安慰剂,为补体通路干预该病提供了随机对照证据。
正文
Presented at #KidneyWk:
An interim analysis of a phase 3 randomized trial involving adults with IgA nephropathy showed that ravulizumab, a terminal complement inhibitor, led to a significantly greater reduction in proteinuria than placebo. Full I CAN trial results: https://nej.md/4iwTFdS
@ASNKidney
来源:NEJM · x.com